Royal Bank of Canada Grows Position in Takeda Pharmaceutical Co. $TAK

Royal Bank of Canada grew its holdings in Takeda Pharmaceutical Co. (NYSE:TAK) by 11.0% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 614,851 shares of the company’s stock after purchasing an additional 60,725 shares during the period. Royal Bank of Canada’s holdings in Takeda Pharmaceutical were worth $11,386,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of TAK. Valeo Financial Advisors LLC raised its holdings in Takeda Pharmaceutical by 6.0% during the 4th quarter. Valeo Financial Advisors LLC now owns 11,220 shares of the company’s stock valued at $175,000 after acquiring an additional 632 shares during the period. Franklin Resources Inc. lifted its holdings in Takeda Pharmaceutical by 3.8% during the 3rd quarter. Franklin Resources Inc. now owns 19,458 shares of the company’s stock worth $285,000 after purchasing an additional 713 shares in the last quarter. Abel Hall LLC lifted its holdings in shares of Takeda Pharmaceutical by 2.3% in the first quarter. Abel Hall LLC now owns 34,099 shares of the company’s stock worth $632,000 after buying an additional 781 shares in the last quarter. Private Trust Co. NA boosted its position in shares of Takeda Pharmaceutical by 84.7% in the fourth quarter. Private Trust Co. NA now owns 1,707 shares of the company’s stock valued at $27,000 after acquiring an additional 783 shares during the period. Finally, Checchi Capital Advisers LLC grew its stake in Takeda Pharmaceutical by 5.7% during the first quarter. Checchi Capital Advisers LLC now owns 14,591 shares of the company’s stock valued at $270,000 after acquiring an additional 786 shares in the last quarter. 9.17% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on TAK. Zacks Research raised shares of Takeda Pharmaceutical from a “strong sell” rating to a “hold” rating in a report on Tuesday, August 4th. Weiss Ratings lowered shares of Takeda Pharmaceutical from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Thursday, July 30th. Finally, Wall Street Zen raised shares of Takeda Pharmaceutical from a “hold” rating to a “buy” rating in a report on Saturday, July 18th. Two equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Takeda Pharmaceutical has a consensus rating of “Hold”.

Takeda Pharmaceutical Stock Performance

NYSE TAK opened at $17.46 on Friday. Takeda Pharmaceutical Co. has a 52-week low of $12.99 and a 52-week high of $18.90. The company has a debt-to-equity ratio of 0.58, a quick ratio of 0.60 and a current ratio of 1.14. The company has a market capitalization of $55.95 billion, a P/E ratio of 51.36 and a beta of -0.08. The company has a fifty day moving average of $16.35 and a 200-day moving average of $17.10.

Takeda Pharmaceutical (NYSE:TAK) last issued its quarterly earnings results on Tuesday, March 31st. The company reported $0.56 earnings per share (EPS) for the quarter. Takeda Pharmaceutical had a return on equity of 10.95% and a net margin of 3.80%.The firm had revenue of $6.90 billion during the quarter. As a group, equities research analysts predict that Takeda Pharmaceutical Co. will post 3.01 EPS for the current fiscal year.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.